{"entity":{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","aka":[],"tldr":"Multiparametric prostate MRI combines three scan sequences, scored 1 to 5 under PI-RADS, and is done before a first biopsy in men with a raised PSA. Needles go to suspicious areas and men with a negative scan can often avoid biopsy altogether, but about one in ten clinically significant cancers is missed.","summary":"Multiparametric prostate MRI combines T2-weighted, diffusion-weighted and dynamic contrast sequences, scored 1 to 5 under PI-RADS v2.1 for the likelihood of clinically significant cancer. It is performed before a first biopsy in men with a raised PSA, so needles can be targeted to suspicious lesions and men with a negative scan can often avoid biopsy. PRECISION (2018) showed MRI-targeted biopsy detected more clinically significant cancer (38% versus 26%) and less insignificant cancer than systematic biopsy, with 28% of men avoiding biopsy; it is now guideline standard before first biopsy. Reader variability remains a limitation and about 10% of significant cancers are missed, so relying on a negative MRI alone in higher-risk men is still debated. AI reading (PI-CAI challenge) matches radiologists. In short, an MRI first finds the cancers that matter and spares many men a biopsy.","status":"standard-of-care","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/PI-RADS","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/PI-RADS"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["imaging","diagnostics"],"technologies":["mri","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["precision-mri"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":["mri"],"notes":[],"principle":"T2-weighted, diffusion-weighted, and dynamic contrast sequences scored 1-5 for likelihood of significant cancer.","strengths":["Fewer and better-targeted biopsies","Reduces overdiagnosis"],"limitations":["Reader variability","Misses ~10% of significant cancers"],"since":2012},"route":"/technologies/mp-mri/","neighbours":{"cancer":[{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/"},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"},{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/"},{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/"},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/"}],"trial":[{"id":"goteborg-2","kind":"trial","name":"GÖTEBORG-2 (MRI-based prostate cancer screening)","route":"/trials/goteborg-2/"},{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/"}],"term":[{"id":"psa-density","kind":"term","name":"PSA density","route":"/terms/psa-density/"},{"id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/"},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/"}],"bottleneck":[{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/"}]}}